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Germline mutations in fi ve autosomal genes involved in interleukin (IL)-12–dependent, 
interferon (IFN)-𝛄–mediated immunity cause Mendelian susceptibility to mycobacterial 
diseases (MSMD). The molecular basis of X-linked recessive (XR)–MSMD remains unknown. 
We report here mutations in the leucine zipper (LZ) domain of the NF-𝛋B essential modula-
tor (NEMO) gene in three unrelated kindreds with XR-MSMD. The mutant proteins were 
produced in normal amounts in blood and fi broblastic cells. However, the patients’ mono-
cytes presented an intrinsic defect in T cell–dependent IL-12 production, resulting in defec-
tive IFN-𝛄 secretion by T cells. IL-12 production was also impaired as the result of a specifi c 
defect in NEMO- and NF-𝛋B/c-Rel–mediated CD40 signaling after the stimulation of 
monocytes and dendritic cells by CD40L-expressing T cells and fi broblasts, respectively. 
However, the CD40-dependent up-regulation of costimulatory molecules of dendritic cells 
and the proliferation and immunoglobulin class switch of B cells were normal. Moreover, the 
patients’ blood and fi broblastic cells responded to other NF-𝛋B activators, such as tumor 
necrosis factor-𝛂, IL-1𝛃, and lipopolysaccharide. These two mutations in the NEMO LZ 
domain provide the fi rst genetic etiology of XR-MSMD. They also demonstrate the impor-
tance of the T cell– and CD40L-triggered, CD40-, and NEMO/NF-𝛋B/c-Rel–mediated induc-
tion of IL-12 by monocyte-derived cells for protective immunity to mycobacteria in humans.
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Mendelian susceptibility to mycobacterial diseases (MSMD) 
(MIM 209950) is a congenital syndrome resulting in predispo-
sition to clinical disease caused by weakly virulent mycobacte-
rial species, such as BCG vaccines and nontuberculous, 
environmental mycobacteria (EM) (1–4). Patients are also sus-
ceptible to the more virulent species Mycobacterium tuberculosis 
(5). Diseases caused by nontyphoidal Salmonella serotypes have 
been observed in just under half the cases (4). Other infectious 
diseases have only rarely been reported, mostly in single pa-
tients. A few patients have suff ered from viral infections, in-
cluding cytomegalovirus and human herpes virus-8 infections, 
and others have had fungal infections with species such as His-
toplasma capsulatum and Paracoccidioidomyces braziliensis. MSMD 
was initially thought to be autosomal recessive in most, if not 
all kindreds, as a result of the high frequency of both multiple-
case sibships and consanguineous kindreds (2, 3).
Figure 1. Clinical phenotypes and NEMO genotypes of patients. 
(A) Pedigrees of three kindreds with NEMO mutations (A, B, and C). Each 
generation is designated by a Roman numeral, and each individual is 
designated by an Arabic numeral. Male patients (in black squares) pres-
ent mycobacterial infections and hemizygous NEMO mutations; asymp-
tomatic female carriers are represented by black dots. The probands are 
indicated by arrows. (B) The teeth of patient P1 (Kindred A, II.4, sparse 
teeth), patient P2 (Kindred B, II.1, conical decidual incisors), and patient 
P3 (Kindred C, II.1, normal teeth). (C) Sequence electrophoregram of 
NEMO complementary DNA in the region corresponding to the mutation. 
Kindred A, P1 presents the mutation A→C leading to the replacement at 
residue 315 of Glu (E) by Ala (A) (E315A). Kindred B, P2 and kindred C, P3 
present the mutation G→A resulting in the replacement of an Arg (R) at 
position 319 by Gln (Q) (R319Q). (D) Schematic representation of the 
NEMO coding region, from exons 2 to 10, and corresponding domains, 
shown in dark gray: the coil-coiled domain 1 (CC1, Leu 93 to Gln 194) 
and coil-coiled domain 2 (CC2, Met 258 to Lys 292), and the leucine 
zipper (LZ, Tyr 308 to Lys 344) and zinc fi nger (ZF, Cys 397 to Cys 417) 
domains. All published hypomorphic NEMO mutations (associated with 
the various forms of EDA-ID) are represented (reference 43). Missense 
and nonsense mutations (amino-acid code) are shown on top, whereas 
splice and frameshift mutations (nucleotide code) are shown on the 
bottom. NEMO mutations in red represent mutations associated with 
mycobacterial infections.
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After the identifi cation in 1996 of germline mutations 
in IFNGR1, encoding the IFN-γ receptor ligand-binding 
chain (IFN-γR1) (6, 7), recessive mutations were reported 
in three other autosomal genes: IFNGR2, encoding the 
 accessory chain of the IFN-γ receptor (8); IL12B, encod-
ing the p40 subunit shared by IL-12 and IL-23 (9); and 
IL12RB1, encoding the β1 chain shared by the receptors 
for IL-12 and IL-23 (10, 11). Defects in IFNGR1 and IF-
NGR2 are associated with impaired cellular responses to 
IFN-γ, whereas defects in IL12B and IL12RB1 are asso-
ciated with impaired IFN-γ production. Allelic heteroge-
neity at these four loci accounts for the existence of nine 
autosomal recessive disorders. After the identifi cation of 
complete defects in which no protein is expressed (6–8, 10, 
11), partial forms of IFN-γR1 (12) and IFN-γR2 (13) de-
fi ciency and complete forms of IFN-γR1 (14), IFN-γR2 
(15), and IL-12Rβ1 (16) defi ciency with surface receptor 
expression were identifi ed.
The identifi cation of MSMD-causing recessive alleles in 
these four autosomal genes led to the discovery of an autoso-
mal dominant form of MSMD, caused by dominant-negative 
alleles of IFNGR1 (17). The mutant alleles exert a dominant-
negative eff ect as the result of overexpression, at the cell 
 surface, of truncated chains that cannot transduce signals. 
Dominant mutations in STAT1, another autosomal gene en-
coding the signal transducer and transactivator of transcrip-
tion 1 (Stat-1), were subsequently identifi ed (18). There are 
two forms of partial Stat-1 defi ciency, depending on whether 
the mutation impairs the phosphorylation of Tyr 701 (18) or 
DNA-binding activity (unpublished data). The two forms of 
partial Stat-1 defi ciency are associated with MSMD because 
these mutations aff ect the activation of IFN-γ–induced Stat-1 
homodimers, but not of IFN-α/β–induced Stat-1-Stat-2-
IRF-9 trimers, in heterozygous cells. A dominant-negative 
mutant allele of IFNGR2 has also been identifi ed, resulting in 
the aberrant subcellular distribution of IFN-γR2, as the re-
sult of a mutation aff ecting the transmembrane domain (19).
In one family fi rst reported in 1991, and more exten-
sively in 1994, it was suggested that MSMD might display 
X-linked recessive inheritance (1, 20–22). Four maternally 
related male patients were found to suff er from severe EM 
disease. These patients’ monocytes were found to be in-
trinsically unable to produce normal levels of IL-12 upon 
stimulation by PHA and T cells (21, 22). Despite the iden-
tifi cation of this immunological phenotype, the molecular 
basis of XR-MSMD has remained elusive. We report here 
the identifi cation of MSMD-causing NEMO mutations in 
this kindred and in two other, unrelated kindreds. These 
mutations do not aff ect NF-κB activation in response to 
most classical activators tested, accounting for the narrow 
spectrum of infections in patients. The two NF-κB essen-
tial modulator (NEMO) mutations identifi ed selectively 
impair the CD40-triggered and NF-κB/c-Rel–mediated 
induction of IL-12 production by monocytes and mono-
cyte-derived dendritic cells, accounting for the susceptibility 
to mycobacteria.
RESULTS
New germline mutations in NEMO in three kindreds
We studied an American multiplex kindred, a French kin-
dred, and a German kindred, each containing one male pa-
tient with sporadic mycobacterial disease (Fig. 1 A). None of 
the six patients in these kindreds displayed the classical devel-
opmental and infectious features of anhidrotic ectodermal 
dysplasia with immunodefi ciency (EDA-ID) (23–25). Coni-
cal incisors in one proband (P2, kindred B, Fig. 1 B) and in 
a second patient (patient III.8, kindred A) nevertheless led us 
to study the X-linked EDA-ID–causing NEMO gene (26) 
(unpublished data). New mutations were found in the cod-
ing region of NEMO in the three probands (Fig. 1 C). P1 
from kindred A presented a nucleotide substitution at posi-
tion 944 (A→C) (Fig. 1 C,  left), leading to the replacement 
of a Glu by an Ala at residue 315 (E315A) (Fig. 1 D). P2 and 
P3 from kindreds B and C, respectively, presented a nucleo-
tide substitution at position 956 (G→A) (Fig. 1 C, middle 
Figure 2. A model of the three-dimensional structure of NEMO. 
(A) Schematic representation of the structural model of the NEMO oligo-
merization domain. The oligomerization domains from three NEMO sub-
units are represented in green, light gray, and dark gray. The LZ motifs 
dock in an antiparallel manner in the crevices defi ned by the central tri-
meric CC2 coiled-coil. (B) Modeling of NEMO oligomerization domain. 
Modeling was based on the coordinates of the HIV-1 gp41 ectodomain, as 
described in Materials and methods. For the sake of simplicity, only one 
LZ domain (LZ[A], in green) is represented, together with the three CC2 
motifs forming the core of the pseudo-six-helix bundle. Amino acids E315 
and R319, mutated in the NEMO protein of the XR-MSMD patients and 
located within the LZ motif, are shown in blue and purple, respectively. 
(C) A close-up of the surrounding environment of E315 (blue) and R319 
(purple) amino acids, which probably form an intramolecular salt bridge. 
Spatially close to these two residues, V280 and K277 (green) are located 
within the CC2 motif of the same NEMO subunit. Q278 (light gray), 
 located within the CC2 motif of the adjacent B subunit (CC2[B]) probably 
forms an intermolecular hydrogen bond with K277.
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and right) resulting in the replacement of an Arg by a Gln at 
position 319 (R319Q) (Fig. 1 D). The two mutations were 
detected in cDNAs, indicating that they corresponded to 
NEMO and not the nearby NEMO pseudogene (27). These 
mutations were not found in 800 unrelated healthy controls 
(1,200 X chromosomes) from 51 ethnic groups (HGDP-
CEPH database). The familial segregation of NEMO in kin-
dred A was consistent with linkage between the observed 
syndrome and this gene (unpublished data). The heterozy-
gous grandmother (I.1), and three other women in kindred 
A (II.3, III.2, III.10), like the mother of P2 in kindred B (I.1) 
and the mother of P3 in kindred C (I.1), were obligate carri-
ers, but displayed no signs of incontinentia pigmenti or EDA 
(unpublished data). These data suggest that these three unre-
lated families suff er from XR-MSMD as the result of mis-
sense mutations in NEMO.
Modeling of the molecular environment of the E315 
and R319 residues
Amino acids E315 and R319 are both located within the 
leucine zipper (LZ) domain of NEMO (Fig. 1 D). Several 
studies have shown that NEMO self-assembles into trimers 
(28, 29). The minimal oligomerization domain of the protein 
consists of the CC2 and LZ coiled-coil motifs, and we re-
cently suggested that these motifs interact to form a pseudo-
six-helix bundle, in which the LZ α-helices dock in the 
crevices defi ned by two of the helices of the central trimeric 
CC2 coiled-coil (Fig. 2 A) (30). A similar scaff old was de-
scribed for the HIV-1 gp41 protein (31). We therefore mod-
eled the NEMO trimeric CC2-LZ domain based on the 
X-ray structure of the gp41 ectodomain (Fig. 2 B). In our 
model, the E315 and R319 residues, located in the middle of 
the LZ domain, face the interior of the coiled coil assembly. 
The environment of the two residues is shown in greater de-
tail in Fig. 2 C. E315 and R319 probably form an intramo-
lecular salt bridge stabilizing the LZ α-helix. Other amino 
acids located in the vicinity of these residues in the model are 
also shown, including K277, from the same NEMO subunit, 
and Q278 from the CC2 motif of an adjacent subunit, which 
probably interact via a hydrogen bond. The E315A and 
R319Q mutations found in XR-MSMD patients would 
break the predicted salt bridge and might induce local plastic-
ity in the LZ helices of the NEMO trimer. Within the highly 
structured CC2-LZ trimer, this might also result in local 
modifi cations to interactions with the central CC2 domains. 
Our structural model therefore also provides a rationale for 
the remarkable similarity and narrowness of the clinical phe-
notypes of the patients described, with NEMO mutations 
disrupting a common salt bridge in the LZ domain.
Normal expression of NEMO protein in blood cells 
and fi broblasts
We assessed NEMO expression by Western blotting extracts 
of EBV-transformed B cells and SV40-transformed fi bro-
blasts with p18 and 3328 antibodies, which recognize the 
N-terminal region of NEMO. The mutant proteins, E315A 
(P1) (not depicted) and R319Q (P2), were expressed in 
similar amounts to wild-type NEMO in EBV-transformed 
B cells (Fig. 3 A). The R319Q protein was also expressed 
in normal amounts in SV40-transformed fi broblasts from 
P2 (Fig. 3 B). Cell lines from P3 (R319Q) and fi broblasts 
from P1 (E315A) were not available. The NEMO X420W 
mutant, which causes the most severe form of EDA-ID 
(24), with osteopetrosis and lymphoedema (OL-EDA-ID), 
was detected only in trace amounts, at a higher molecular 
weight, on Western blots of EBV-transformed B cells and 
SV40-transformed fi broblasts (Fig. 3, A and B). As a negative 
control (C−) (Fig. 3 B), no NEMO was detected in SV40-
transformed fi broblasts bearing a large amorphic deletion in 
NEMO (27). We assessed intracellular NEMO expression by 
fl ow cytometry, using antibody 278–396, which recognizes 
the C-terminal region of NEMO (32). NEMO was normally 
Figure 3. Expression of NEMO in the patients. NEMO protein, de-
tected by Western blotting with two specifi c antibodies, 3328 and p18, 
which recognize different parts of the N-terminus of NEMO (A) EBV-
transformed B cell lines and (B) SV-40–transformed fi broblastic cell lines 
from a healthy donor (C+), an OL-EDA-ID patient carrying the X420W 
NEMO mutation, P2 and an SV-40–transformed fi broblastic cell line from 
a NEMO-defi cient fetus as a negative control (C−). Intracellular staining 
of NEMO with a specifi c antibody recognizing amino acids 278–396 and 
detected by fl ow cytometry in (C) EBV-transformed B cell lines and 
(D) SV40-transformed fi broblastic cell lines from healthy control (C+), 
an OL-EDA-ID patient, P1 and P2. (E) Purifi ed monocytes (left) and T cells 
(right) from a healthy control (C+) and P2.
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expressed in EBV-transformed B cells (P1, P2) and SV40-
transformed fi broblasts (P2) from the patients, taking seven 
and fi ve control cell lines, respectively, as a reference, but not 
in fi broblasts bearing a large deletion in NEMO (Fig. 3, C 
and D). NEMO was barely detectable in EBV-transformed B 
cells and SV40-transformed fi broblasts from the patient with 
OL-EDA-ID. The intracellular expression of NEMO was 
also normal in freshly isolated monocytes and T cells from 
P2 (Fig. 3 E). Thus, levels of NEMO expression were strictly 
normal in patients bearing the E315A and R319Q muta-
tions as shown by Western blotting and fl ow cytometry in 
hematopoietic and nonhematopoietic cell lines and in freshly 
prepared blood cells.
Response of blood cells and fi broblasts to LPS, 
R-848, TNF-𝛂, and IL-1𝛃
NEMO mutations in patients with EDA-ID are usually asso-
ciated with impaired cellular responses to multiple stimuli, 
including LPS (via TLR-4), TNF-α, and IL-1β  (24, 25). 
We thus stimulated whole blood cells from the patients and 
Figure 4. NF-𝛋B activation in leukocytes and fi broblasts. 
Healthy controls (C+, ●), OL-EDA-ID patient (△), SV-40–transformed 
fi broblastic cell line from NEMO-defi cient fetus (C−,▲), P2 (□), and P3 
(○). (A) IL-10 production by whole blood cells from 10 healthy controls 
and P2 and P3, upon stimulation with LPS (1 μg/ml), TNF-α (20 ng/ml), 
IL-1β (10 ng/ml), and PMA/ionomycin (10−7/10−5 M) for 48 h. (B) TNF-α 
production by EBV-transformed B cells after 24 h of TLR7/8 activation 
by R-848 agonist. (C) IL-6 and IL-8 production by SV-40–transformed 
fibroblastic cell lines from nine healthy controls and from 
P2 and C− (three experiments each for P2 and C−), after 24 h of 
TNF-α and IL-1β stimulation. All cytokines were determined by sandwich 
ELISA. (D) DNA-binding activity in nuclear extracts from fi broblastic 
cell lines after TNF-α (20 ng/ml) and IL-1β (10 ng/ml) activation for 
various lengths of time, as detected with a radio-labeled DNA probe 
by EMSA (top), and IκBα degradation and GAPDH expression, detected 
by Western blotting, in the corresponding cytoplasmic extracts 
 (bottom). The results shown are representative of at least two 
 independent experiments.
1750 X-LINKED SUSCEPTIBILITY TO MYCOBACTERIA | Filipe-Santos et al.
10 healthy controls with LPS, TNF-α, IL-1β, and PMA/
ionomycin, and measured the induction of IL-6 (unpublished 
data), IL-10, and TNF-α. The three patients displayed nor-
mal levels of IL-10 (Fig. 4 A), IL-6, and TNF-α (not de-
picted) production upon stimulation with LPS, IL-1β, and 
PMA plus ionomycin. IL-10 was also induced by TNF-α in 
P2 and P3, although to lower levels (Fig. 4 A). EBV-trans-
formed B cells from P2 responded normally to R-848, an ag-
onist of TLR-7/8, in terms of TNF-α production (Fig. 4 B). 
We then assessed the impact of NEMO mutations in fi bro-
blasts from P2, a NEMO-defi cient fi broblastic cell line bear-
ing a large NEMO deletion, and fi broblasts from nine healthy 
controls. Fibroblasts from P2 produced normal amounts of 
IL-6 and IL-8 in response to both IL-1β and TNF-α (Fig. 4 C). 
In contrast, fi broblasts from all EDA-ID patients tested, bear-
ing other NEMO mutations, showed various levels of im-
pairment of IL-6 and IL-8 production (unpublished data). 
We assessed IκBα cytoplasmic degradation by Western blot-
ting and the κB-binding activity of nuclear extracts by elec-
trophoretic mobility shift assays. In contrast with what was 
observed in fi broblasts from the OL-EDA-ID patient bearing 
NEMO mutation X420W (24), both IκBα degradation and 
κB binding activity were completely normal in fi broblasts 
from P2 (Fig. 4 D). Thus, the NEMO–NF-κB signaling 
pathway in response to TLR4, 7, and 8 agonists, IL-1β, and 
TNF-α, was normal in SV40-fi broblastic and EBV-trans-
formed B cell lines from our patients.
Impaired production of IL-12 and IFN-𝛄 by peripheral blood 
mononuclear cells upon PHA activation
We previously reported that PBMCs from P1 produced small 
amounts of IFN-γ upon stimulation with PHA (21, 22). 
PBMCs from P2 and P3 produced normal amounts of IFN-γ 
in response to PMA/ionomycin but not in response to PHA 
or CD3 stimulation, with normal levels determined as those 
for 10 healthy controls (Fig. 5 A). In these conditions, the 
impaired production of IL-12 was previously shown to ac-
count for poor IFN-γ production by PBMCs in P1 (21), 
consistent with the poor production of IFN-γ observed in 
blood cells from IL-12p40- and IL-12Rβ1–defi cient patients 
(9, 11, 33). Accordingly, PBMCs from P2 and P3 produced 
only small amounts of IL-12 after PHA stimulation, which 
were not complemented by adding IFN-γ (Fig. 5, B and C). 
In contrast, the addition of IL-12 partially complemented 
IFN-γ production (Fig. 5 A). As a control, the PHA-driven 
production of TNF-α and IL-10 by P2 and P3 was similar to 
that in 10 healthy controls (unpublished data). The produc-
tion of IL-12 and IFN-γ was also normal upon stimulation 
with LPS and PMA/ionomycin, respectively (Fig. 5, A–C). 
Moreover, the production of IL-12 and IFN-γ by whole 
blood cells stimulated with live BCG (alone or with IFN-γ or 
IL-12) was normal in P2 and P3 (Fig. 5 D). Thus, the three 
probands displayed selective impairment of IL-12 and IFN-γ 
production by PBMCs upon stimulation with PHA or CD3. 
In contrast, the production of IL-12 was normal in response 
to LPS and BCG and that of IFN-γ was normal in response 
to PMA/ionomycin and BCG. Overall, the cellular pheno-
type of impaired IL-12–dependent production of IFN-γ by 
PHA-stimulated PBMCs is suggestive of a common patho-
genic mechanism of predisposition to mycobacterial disease 
associated with NEMO mutations E315A and R319Q.
Impaired IL-12 secretion by PHA-stimulated monocytes 
and T cells
We previously described a specifi c defect in IL-12 produc-
tion by P1 monocytes upon PHA stimulation in the presence 
of control T cells (21, 22). We tested cells from P2 and P3 in 
a similar coculture assay and measured the production of IL-
12p70, IL-12p40, and IFN-γ by ELISA (Fig. 6 A). These cy-
tokines were produced in very small amounts or not at all in 
monocytes stimulated with PHA in the absence of T cells or 
in T cells in the absence of monocytes. P2 and P3 monocytes 
cocultured with autologous or healthy T cells produced 
much less IL-12p70, IL-12p40, and IFN-γ than control 
monocytes cocultured with autologous, P2, or P3 T cells. 
The T lymphocytes of these patients produced IFN-γ after 
costimulation with control monocytes and PHA. The low 
levels of IFN-γ secretion were the result of poor IL-12 
 production as indicated by (a) the complementation provided 
by recombinant IL-12 (but not IL-23) (unpublished data) 
and (b) the poor production of IFN-γ documented with 
IL-12p40–defi cient monocytes or IL-12Rβ1–defi cient 
Figure 5. IL-12 and IFN-𝛄 production by leukocytes. Cytokine pro-
duction by PBMCs from 10 healthy donors, (C+, ●), P2 (□), and P3 (○) 
in response to PHA, alone or in combination with recombinant IL-12 (20 
ng/ml), IL-23 (20 ng/ml), or IFNγ (5,000 UI/ml), anti-CD3 (10 ng/ml), LPS 
(1 μg/ml) and PMA/ionomycin (10−7/10−5 M). (A) IFN-γ, (B) IL-12p70, 
(C) IL-12p40 production. (D) Cytokine production by whole blood cells 
from 50 healthy donors, P2, and P3 upon stimulation with live BCG alone 
or in combination with IL-12 (20 ng/ml) or IFN-γ (5,000 IU/ml): IFN-γ 
(top), IL-12p70 (middle), and IL-12p40 (bottom) secretion. For each patient, 
the results shown are representative of two independent experiments.
JEM VOL. 203, July 10, 2006 1751
ARTICLE
T cells (unpublished data). Certain monokines, such as IL-6, 
G-CSF, and MCP-1, were poorly induced, whereas others 
were induced in normal (IL-4, IL-10) or large (IL-5, IL-13) 
amounts by monocytes from P2 and P3, indicating that these 
cells were not globally unresponsive (Fig. 6 B and not de-
picted). Two other lymphokines (IL-2, IL-4) were not af-
fected and the production of IL-17 was impaired. Finally, 
cytokines secreted by T cells and monocytes (TNF-α, IL-7, 
IL-10, and GM-CSF) were normally induced. All three pro-
bands had a specifi c immunological phenotype in which IL-
12 production by monocytes in response to PHA and T cells 
was aff ected. Impaired IFN-γ production does not refl ect 
an intrinsic T cell defect and is instead a consequence of im-
paired IL-12 production by monocytes.
PHA-activated T cell–dependent monocyte secretion 
of IL-12 is driven by CD40
The two NEMO mutations exerted their eff ects downstream 
from monocyte receptors triggering the induction of IL-12. 
The CD40 signaling pathway has been shown to be critical 
for the T cell–dependent induction of IL-12 in monocytes 
and dendritic cells (34–37). After PHA stimulation, PBMCs 
from CD40- and CD40L-defi cient patients (38) produced 
much lower levels of IL-12 and IFN-γ than did PBMCs 
from 10 healthy controls (unpublished data), consistent with 
previous data (39). The induction of IL-12 by LPS and that 
of IFN-γ by PMA/ionomycin were normal (unpublished 
data). IL-12 induction was abolished if CD40L-defi cient 
T cells were cocultured with healthy or CD40L-defi cient 
monocytes, resulting in low levels but not the total absence 
of IFN-γ production (Fig. 7 A). Conversely, normal IL-12 
induction was observed if control or CD40L-defi cient mon-
ocytes were mixed with T lymphocytes from a healthy donor. 
Low levels of IFN-γ induction were associated with the pres-
ence of small amounts of IL-12 in this assay. IL-12 induction 
was abolished if CD40-defi cient monocytes were incubated 
with CD40-defi cient or normal T cells (Fig. 7 B). Paradoxi-
cally, IFN-γ secretion was not signifi cantly impaired, perhaps 
refl ecting the direct cross-linking of CD40L by PHA (40). 
In contrast, control monocytes produced normal amounts 
of IL-12 when cultured with control or CD40-defi cient 
T cells. Our fi ndings for the monocyte–T cell coculture assay 
unambiguously indicate that the engagement of the mono-
cyte CD40 by CD40L-expressing T cells is required for the 
optimal induction of IL-12 production. These data suggest 
that the NEMO mutations in P1, P2, and P3 were patho-
genic as a result of their impact on CD40 signaling within 
monocytes, leading to low levels of IL-12 secretion upon 
T cell stimulation.
NEMO mutation impairs CD40 signaling in dendritic cells 
but not B cells
We assessed the responses to CD40 stimulation of cells from 
our patients. We fi rst incubated purifi ed monocytes from 
P2 with mouse fi broblastic L cells (L-cells) and L-cells sta-
bly transfected with a construct encoding human CD40L 
(L-cells-hCD40L). Monocytes from P2 did not produce 
IL-12, IL-6, and TNF-α upon stimulation with L-cells-
hCD40L (unpublished data). We then tested monocyte-de-
rived dendritic cells (MDDCs) as DCs are major producers 
of IL-12 in vivo. MDDCs produce large amounts of IL-12 
upon CD40 stimulation in vitro (36). MDDCs from P2 and 
P3 were activated with LPS plus IL-1β, L-cells, or L-cells-
hCD40L with or without IL-1β. MDDCs from P2 and P3 
displayed severely impaired cytokine production in response 
to L-cells–hCD40L but not in response to LPS plus IL-1β 
(Fig. 7 C), whereas induction of the costimulatory molecules 
Figure 6. IL-12 and IFN-𝛄 production by cocultured monocytes 
and T cells from the patients studied and healthy controls. 
(A) IL-12p70, IL-12p40, and IFN-γ production, measured using classical 
sandwich ELISA, in a mixture of purifi ed monocytes and T cells, as indi-
cated upon stimulation with PHA. The results shown are representative 
of three independent experiments for P2 and one for P3. (B) The same 
coculture supernatants were analyzed for a multiplex of 16 cytokines, 
using the Bioplex array. Each column represents the data for one monocyte–
T cell coculture system, and all four columns correspond to the same 
experiment. Each row corresponds to one cytokine. The gray-scale bar 
indicates the magnitude of cytokine expression, using the control/control 
(C/C) coculture system as a reference. For each data point, the amount of 
cytokine produced in the unstimulated system was subtracted from that 
produced in the PHA-activated system, and the result obtained was 
 compared with the reference value (C/C). The production of *MCP-1 and 
*MIP-1β by monocytes was PHA-dependent but T cell–independent, as 
monocytes responded to PHA by producing large amounts of these cyto-
kines, whereas the addition of T cells did not increase cytokine production. 
The defects in the production of IL-6, IL-12p70, G-CSF, IFN-γ, and MCP-1 
were confi rmed in three independent experiments on blood cells from P2 
and one experiment on blood from P3.
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CD80 and CD86, unlike that of CD40, was maintained (Fig. 
7 D). These data are consistent with our previous observa-
tions in a child with a severe NEMO mutation associated 
with OL-EDA-ID and severe mycobacterial infection (24). 
MDDCs from P2 and P3 expressed normal levels of NEMO 
(Fig. 7 E). B cells from P2 produced normal amounts of IgE 
in response to costimulation with IL-4 and CD40L, as shown 
by ELISA, with data from 20 healthy controls and a CD40-
defi cient patient used as a reference (Fig. 7 F). Moreover, 
B cell proliferation, as assessed by the measurement of [3H] 
thymidine incorporation, was also normal (unpublished 
data). These data suggest that the CD40 signaling pathway 
was not aff ected in B cells in vitro, consistent with the normal 
B cell switch and antibody response in vivo in our patients. 
Altogether, these fi ndings suggest that the patients with 
XR-MSMD bearing the E315A and R319Q mutations in 
NEMO suff ered from mycobacterial disease as a result of the 
impaired IL-12 production by monocytes and dendritic cells 
after stimulation with the CD40L on T cells.
Delayed nuclear accumulation of NF-𝛋B/c-Rel 
in CD40-stimulated dendritic cells
We evaluated the impact of the NEMO mutations identifi ed 
by confocal microscopy analysis of the subcellular distributions 
Figure 7. The impact of CD40 and CD40L defi ciency on IL-12 and 
IFN-𝛄 production. IL-12p70, IL-12p40, and IFN-γ production, measured 
by classical sandwich ELISA, in a mixture of purifi ed monocytes and T cells, 
as indicated, upon stimulation with PHA from a healthy donor with 
(A) CD40L- and (B) CD40-defi cient PBMCs. MDDCs obtained from two 
healthy controls (C2 and C3), P2 and P3, after 24 h of incubation alone or 
with LPS (1 μg/ml) plus IL-1β (10 ng/ml) as a control of CD40-independent 
activation, cocultured with L-cells transfected with human CD40L 
(L-cell-hCD40L) and nontransfected L-cells (L-cell): (C) IL-12p70, IL-12p40, 
TNF-α, and IL-6 production, measured by classical sandwich ELISA, and 
(D) FACS analysis of cell surface expression of CD40, CD80, and CD86 
 costimulatory molecules gating on CD1a-positive MDDCs. (E) Intracellular 
staining of NEMO protein in MDDCs from P2 and P3, and their respective 
controls (C2 and C3) in the experimental conditions of Fig. 3. (F) IgE secre-
tion by B cells in vitro, as measured by ELISA, after the activation of PBMCs 
from 20 healthy controls (C+, ●), P2 (□), and a CD40-defi cient patient as 
the negative control (C−,△), with soluble CD40L in combination with IL-4. 
The results shown are representative of two independent experiments.
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of the NF-κB subunits RelA (p65) and c-Rel in MDDCs 
from P2 and a healthy control, unstimulated and in response 
to LPS, IL-1β, TNF-α, mouse L-cells, or human CD40L-ex-
pressing mouse L-cells. LPS treatment resulted in the nuclear 
accumulation of RelA and c-Rel in MDDCs from both the 
healthy control and P2 (Fig. 8 A). IL-1β induced the trans-
location of RelA, but not of c-Rel, in MDDCs from both 
the healthy donor and P2 (unpublished data). The nuclear 
translocation of RelA in response to TNF-α seemed to be 
less effi  cient in MDDCs from P2 (Fig. 8 A), possibly account-
ing for the weak induction of IL-10 in PBMCs (Fig. 4 A). 
The translocation of RelA in response to CD40 stimulation 
was normal in MDDCs from P2 up to 8 h after stimulation 
(Fig. 8 B). In contrast, the nuclear accumulation of c-Rel 
in response to CD40 was clearly impaired in  MDDCs from 
P2, 2 (Fig. 8 B) and 5 h after stimulation (not depicted). 
Only after 8 h of stimulation was c-Rel accumulation de-
tected in the nuclei of MDDCs from P2 (Fig. 8 B). These 
data strongly suggest that the NEMO mutation identifi ed in 
P2 impairs CD40-triggered NF-κB activation by delaying 
the nuclear accumulation of c-Rel. They also suggest that 
CD40-driven, NEMO-dependent IL-12 production in hu-
man MDDCs depends on c-Rel, as previously shown in mice 
(41, 42). Furthermore, our data indicate that the R319Q and 
E315A mutations in the NEMO LZ domain are associated 
with XR-MSMD because they impair the T cell–dependent, 
CD40-triggered, NF-κB/c-Rel–mediated induction of IL-12
in monocytes and dendritic cells (Fig. 8 C).
Figure 8. Endogenous RelA/p65 and c-Rel localization in MDDCs 
upon CD40L stimulation. Isolated monocytes from a healthy control 
(C+) and P2 were cultured for 8 d with GM-CSF and IL-4 to generate 
MDDCs. MDDCs were serum starved for 20 h before activation. MDDCs 
were incubated alone or activated with (A) LPS (1 μg/ml), TNF-α (20 ng/ml), 
and (B) cocultured with L-cells transfected with human CD40L (L-cell-
hCD40L) or nontransfected L-cell line (L-cell) and fi xed by incubation in 
4% PFA. MDDCs were surface stained with mouse anti–human CD1a and 
Cy3-conjugated goat anti–mouse IgG (red) and endogenous RelA and 
c-Rel were stained with Alexa-488–conjugated goat anti–rabbit IgG 
against primary rabbit antibody (green). The nucleus was stained with 
DAPI (not depicted). (C) Schematic representation of cytokine production 
and cooperation between monocytes/dendritic cells and T cells. The IL-
12/IFN-γ loop and the CD40L-activated CD40 pathway, mediating coop-
eration between T cells and monocyte/dendritic cells, are crucial for 
protective immunity to mycobacterial infection in humans. IL-12 pro-
duction is controlled by both IFN-γ and CD40-NEMO-NF-κB signaling. 
 Mutant molecules in patients with MSMD are indicated in gray. Allelic 
heterogeneity of the fi ve autosomal disease-causing genes results in the 
defi nition of 12 genetic disorders. The NEMO mutations in the LZ domain 
mostly impair CD40-NEMO-dependent pathways and defi ne the X-linked 
form of MSMD.
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D I S C U S S I O N 
We describe here the fi rst genetic etiology of XR-MSMD, a 
syndrome clinically defi ned for the fi rst time in 1994 in a 
multiplex American kindred (1, 21), after the publication of 
individual case reports (20). The four patients from this  family 
carried the E315A mutation in NEMO. XR-MSMD is not 
limited to a single family, as a diff erent, but related NEMO 
mutation, R319Q, was found in two unrelated European 
boys, from France and Germany. NEMO is the sixth MSMD-
causing gene to be identifi ed, after the identifi cation of 
 IFNGR1 in 1996 (6, 7), IFNGR2, IL12B, and IL12RB1 in 
1998 (8–11), and STAT1 in 2001 (18) (Fig. 8 C). It is the 
sixth genetic defect associated with MSMD but the 13th ge-
netic etiology of this syndrome, given the considerable allelic 
heterogeneity of previously reported defects of the IL-12–
IFN-γ circuit (15) (unpublished data). One of our patients 
with EM disease (II.4 in kindred A) also suff ered from miliary 
tuberculosis in childhood, and two of our probands (P2 and 
P3) probably suff ered from tuberculosis, as the sole infectious 
phenotype suggested by consistent histological results and 
strongly positive tuberculin skin tests. Patients with BCG and 
EM diseases and otherwise healthy children with severe tu-
berculosis should therefore be investigated for NEMO muta-
tions (5). The possibility of NEMO mutations cannot be 
excluded by the absence of developmental signs, as shown in 
four of our six patients and in two other recently reported 
patients (43).
We can now suggest a rationale for the pathogenesis of 
mycobacterial diseases in patients with XR-MSMD. The 
two causal NEMO mutations impair CD40 signaling in 
monocytes and dendritic cells, delaying the nuclear accu-
mulation of NF-κB/c-Rel and impairing IL-12 secretion 
upon stimulation by CD40L-expressing T cells. In turn, im-
paired IL-12 production by antigen-presenting cells results 
in impaired IFN-γ production by T cells. X-linked NEMO 
is thus physiologically connected to the fi ve autosomal IL-
12/23–IFN-γ circuit genes known to cause MSMD (4). 
These data are consistent with the observation that CD40-
defi cient (44) and CD40L-depleted mice (45) are susceptible 
to Mycobacterium avium infections. CD40L-defi cient mice 
are also susceptible to BCG and CD40-defi cient mice are 
susceptible to Mycobacterium tuberculosis (46, 47). Moreover, 
CD40L-defi cient patients frequently develop localized dis-
ease caused by BCG, and severe tuberculosis (5, 48). How-
ever, human CD40 and CD40L are not recognized as bona 
fi de MSMD-causing genes, as CD40- and CD40L-defi cient 
patients have never been reported to suff er from dissemi-
nated BCG or EM disease. This implies that pathways other 
than CD40–NEMO–IL-12, such as the TNF-α signaling 
pathway (Figs. 4 A and 8 A) (49), are probably involved 
in the pathogenesis of diseases caused by EM, at least, in 
patients with mutations in the NEMO LZ domain. In any 
event, human phagocytes and dendritic cells require T cell 
stimulation via CD40, NEMO, and c-Rel to produce the 
amounts of IL-12 necessary to control mycobacteria in natu-
ral conditions of infection (50).
Null mutations in NEMO are lethal in utero in male fe-
tuses (27). Patients with hypomorphic mutations in NEMO 
suff er from XR-EDA-ID (23–26). To date, 36 patients 
bearing 28 diff erent NEMO mutations have been described 
(23–27, 32, 43, 51–55) (unpublished data). 11 out of the 
known 36 XR-EDA-ID patients have developed severe my-
cobacterial infection, mostly caused by M. avium. However, 
these patients also suff ered from infections caused by many 
other microorganisms. In contrast, fi ve of our six patients 
presented mycobacterial disease as their sole invasive infec-
tion. The invasive Haemophilus infl uenzae b infection in one 
of our patients may not have occurred by chance. Similarly, 
two out of the six patients had conical incisors (decidual 
teeth in one and permanent teeth in the other), implying 
that the penetrance of these particular NEMO genotypes 
was low (but not null) for pyogenic infections and devel-
opmental defects, but high for mycobacterial disease. Our 
report stresses the heterogeneity of phenotypes associated 
with hypomorphic NEMO mutations. Two patients with 
XR-EDA-ID, both with the X420W genotype, presented 
XR-OL-EDA-ID (24, 53, 54). Most patients present the 
less severe clinical syndrome of XR-EDA-ID, with typi-
cal (23–25) or hidden (conical incisors) (26) developmental 
signs and multiple infections. Two other patients with se-
vere infections but no developmental disorder were recently 
reported (43). Finally, we report here two novel NEMO 
mutations, responsible for MSMD in six patients. All six pa-
tients are selectively susceptible to mycobacteria and display 
selective impairment of the CD40-dependent induction of 
IL-12 in antigen-presenting cells. These fi ndings provide 
the fi rst link between a NEMO genotype and immunologi-
cal and infectious phenotypes.
Why do these two mutations have selective eff ects? The 
E315A and R319Q mutations are located in the LZ domain 
of NEMO and do not aff ect protein expression. Residues 
E315 and R319 probably form a salt bridge that is disrupted 
by the two pathogenic mutations (Fig. 2 C). The two muta-
tions may induce local plasticity in a region of the LZ do-
main critical for signaling via CD40, but less important for 
other signaling pathways. However, CD40 signaling was not 
totally abolished in dendritic cells from our patients, as the 
nuclear accumulation of RelA, and the induction of CD80 
and CD86 were normal, whereas the induction of CD40 was 
not. These fi ndings are consistent with the normal CD40-
mediated induction of HLA-II and CD86 previously re-
ported in dendritic cells from a patient with OL-EDA-ID 
(24). It is unknown whether the CD40–CD80/86 and 
CD40–HLA-II pathways are truly NEMO independent or 
whether they are unaff ected by the NEMO mutations tested. 
The E315A and R319Q NEMO mutations impair at least 
one CD40 signaling pathway involving NF-κB–c-Rel in 
monocytes and dendritic cells, but they have no signifi cant 
eff ect on B cells, in vivo and in vitro, unlike other previously 
reported NEMO mutations (24, 25, 52, 55). In conclusion, 
specifi c NEMO mutations may selectively target the CD40–
NF-κB–c-Rel signaling pathway in monocytes and dendritic 
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cells, preventing the production of suffi  cient quantities of 
IL-12 after T cell stimulation. This results in impaired IFN-
γ–mediated immunity and predisposition to mycobacterial 
diseases (Fig. 8 C).
MATERIALS AND METHODS
Case reports. The fi rst family (kindred A) with XR-MSMD has been 
 described elsewhere (1, 20–22). None of the family members were vacci-
nated with BCG. Severe M. avium infection was documented in four mater-
nally related male family members in two successive generations (Fig. 1 A; 
patients II.1, II.4, III.7, and III.8). The clinical features of patient 1 (P1, II.4), 
the index case, have been described elsewhere (1, 20). In brief, at the age of 
13 yr, P1 presented granulomatous cutaneous lesions, thought to be sarcoid. 
Extensive erosive lesions on the face and arm were subsequently found to be 
the result of M. avium complex infection. Treatment with rifampicin, eth-
ambutol, clofazimine, isoniazid and streptomycin was initiated. After 2.5 yr 
of therapy, smears and cultures of skin from the patient’s face and arm re-
mained positive for M. avium complex X cluster. Intensive antibiotic and 
IFN-γ therapy has led to periods in which the skin has healed and cultures 
have tested negative, but this patient has frequently displayed intermittent 
mycobacteremia over the last 10 yr. Three other family members also devel-
oped disseminated M. avium complex infection. Patient II.1 was cured of 
miliary tuberculosis at the age of 6 yr. Disseminated M. avium infection oc-
curred in this patient at the age of 40 yr, and was never completely eradi-
cated. The patient died of Enterobacter bacteremia complicating parenteral 
nutrition at the age of 48 yr. Patient III.7 was successfully treated for dissemi-
nated M. avium infection at the age of 5 yr, but died in an automobile acci-
dent at the age of 10. His brother, patient III.8, had recurrent Haemophilus 
infl uenzae bacteremia at the age of 6 yr. At the age of 14 yr, he presented dis-
seminated M. avium complex infection involving abdominal lymph nodes 
and blood. Overt signs of ectodermal dysplasia (conical teeth, hypodontia, 
hypotrichosis, abnormal hair whorl) were evaluated. This patient has re-
mained mycobacteremic despite treatment with multiple antibiotics and 
IFN-γ. Sparse teeth were the only developmental abnormality on physical 
examination, and long went unrecognized in patient 1 (Fig. 1 B, left). Cells 
of the various blood lineages and lymphoid subsets (CD3, CD4, CD8, 
CD20, CD16, CD56) were present in normal numbers. T cells proliferated 
normally in vitro in  response to mitogenic (PHA) and antigenic (recall anti-
gens) stimulation. In P1, serum levels of Ig isotypes (IgG, IgM, IgA, IgE, 
IgD) were normal for age, and there was a normal Ab response to protein 
and polysaccharide antigens.
The second family (kindred B) included a single patient (P2, II.1), an 
8-yr-old boy, born to unrelated parents of Italian and Serbian descent liv-
ing in France (Fig. 1 A). At the age of 2 mo, this child was vaccinated with 
BCG. At the age of 2 yr, he was hospitalized for persistent low-grade fever 
(38°C) with night sweats, cough, and cervical and inguinal lymphadenopa-
thy. Serum C-reactive protein (CRP) levels (31 mg/l) and erythrocyte 
sedimentation rate (ESR) were high (32 mm/h), as was leukocyte count, at 
15,200 leucocytes/mm3. Chest X-ray and pulmonary function tests were 
normal. Urine, gastric, and blood cultures for mycobacteria were negative, 
but the patient had a strongly positive tuberculin skin test (TST) (24-mm 
induration). The patient was treated with isoniazid and rifampicin for 6 
mo, and his condition improved. Approximately 1 yr after the end of treat-
ment, he was hospitalized for cervical lymphadenitis and prolonged fever. 
The TST was again positive (10 mm). Four lymph nodes were excised and 
a biopsy revealed granulomas with no visible acid-fast bacilli. Cultures 
were negative. The patient also had diarrhea, with Salmonella enteritidis 
identifi ed in the stools, from which he recovered spontaneously. He is now 
8 yr old and clinically well with no treatment. Conical decidual incisors 
were the only developmental abnormality on physical examination, and 
this abnormality was long unrecognized (Fig. 1 B, middle). Permanent 
teeth were normal in shape and number, as shown by clinical examination 
and mandibular X ray (unpublished data). Cells of the various blood line-
ages and lymphoid subsets (CD3, CD4, CD8, CD19, CD16, CD56) were 
present in normal numbers. T cells proliferated normally in vitro in re-
sponse to mitogenic (PHA) and antigenic (recall antigens) stimulation. The 
NBT assay and chemioluminescence of PMNs were normal. Serum levels 
of Ig isotypes (IgG, IgM, IgA, IgE, IgD) were normal for age, and there 
was a normal Ab response to protein antigens. Serum titers of allo-hemag-
glutinins were normal (group B). The patient had no detectable antibodies 
against polysaccharide antigens at the age of 6 yr, when he was immunized 
with 23-valent nonconjugated pneumococcal vaccine, but mounted a nor-
mal response at the age of 7 yr, after two injections of nonconjugated 
pneumococcal vaccines.
The third family (kindred C) included a single patient (P3, II.1), an 11-yr-
old boy, born to unrelated German parents living in Germany (Fig. 1 A). 
He was not vaccinated with BCG. At the age of 1 yr, he was hospitalized for 
a cervical abscess caused by Haemophilus infl uenzae b, which responded well 
to surgery and antibiotic treatment. At 9 yr of age, he was hospitalized for 
persistent low-grade fever (38°C) of unknown origin. He presented spleno-
megaly, marked hypergammaglobulinemia, and granulocytopenia. After his 
discharge from the hospital, he suff ered recurrent infections, including bron-
chitis and pneumonitis. At the age of 10 yr and 4 mo, he had a strongly posi-
tive TST (20-mm induration), whereas negative results had been obtained 
for this test on three previous occasions, at the ages of 7, 8, and 9 yr. At the 
same time, an ELISPOT assay for IFN-γ after ESAT-6 stimulation was neg-
ative. Chest X-ray showed no mediastinal lymph node enlargment, but did 
show infi ltration of the lower parts of both lungs. A tentative diagnosis of 
mycobacterial disease was made, and the patient was treated with isoniazid 
for 3 mo. This treatment was stopped as it seemed to cause headaches, but 
the patient was subsequently treated with cefpodoxime prophylaxis. No de-
velopmental abnormalities, not even conical teeth, were observed on physi-
cal examination (Fig. 1 B, right). Mandibular X-ray indicated an absence of 
hypodontia. Cells of the various blood lineages and lymphoid subsets (CD3, 
CD4, CD8, CD19, CD16, CD56) were present in normal numbers. T cells 
proliferated normally in vitro in response to mitogenic (PHA) and antigenic 
(recall antigens) stimulation. The results of NBT and dihydrorhodamine tests 
were normal. Serum levels of the immunoglobulin IgG, IgM, and IgD iso-
types were high (maximum titers: IgG 70.85 g/liter, IgM 1.54 g/liter, and 
IgD 304 IU/ml). Serum IgA and IgE levels were normal. There was a nor-
mal Ab response to protein antigens. There were no allo-hemagglutinins 
(group A). The patient had detectable, but very low titers of antibodies 
against polysaccharide antigens at the age of 11 yr, before vaccination. After 
vaccination with 23-valent nonconjugated vaccine at the age of 11 yr, titers 
rose and reached normal levels.
Mutations in the fi ve known MSMD-causing autosomal genes 
 (IFNGR1, IFNGR2, STAT1, IL12B, IL12RB1) were excluded in the three 
kindreds by means of genetic and immunological assays (unpublished data). 
Other patients with well-defi ned genetic defects were enrolled in our study, 
including patients with IL-12p40 defi ciency, IL-12Rβ1 defi ciency, IFN-
γR1 defi ciency, CD40 defi ciency, and CD40L defi ciency. Their genetic 
 lesions are available upon request. Our study was conducted according to the 
principles expressed in the Helsinki Declaration and was approved by our 
Institution Review Boards. An informed consent was provided by all pa-
tients studied, or by their parents, in the case of children.
Blood cell culture and stimulation. Whole blood samples were diluted 
1/2 in RPMI 1640 (GIBCO BRL) and infected by incubation with live 
M. bovis BCG (Pasteur substrain), at a multiplicity of infection of 20:1, alone 
or with recombinant IFN-γ (5,000 IU/ml; Imukin, Boehringer Ingelheim) 
or recombinant IL-12p70 (20 ng/ml; R&D Systems), LPS (from Salmonella 
minnesota, 1 μg/ml; Sigma-Aldrich), TNF-α (20 ng/ml; R&D Systems), 
IL-1β (10 ng/ml; R&D Systems), phorbol 12-myristate 13-acetate (PMA) 
(10−7 M; Sigma-Aldrich) with ionomycin (10−5 M; Sigma-Aldrich) and 
 supernatants were recovered after 14 and 48 h. Cytokine production was 
normalized according to the number of PBMCs in the individual tested. PBMCs 
were obtained from patients and healthy donors by centrifuging heparin-
treated blood diluted 1/2 in RPMI 1640 on Ficoll-Paque Plus (GE Healthcare), 
followed by isolation in mononuclear cell medium. PBMCs were cultured in 
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RPMI 1640 medium (GIBCO BRL) supplemented with 10% heat-
i nactivated pooled FBS (GIBCO BRL), referred to as complete RPMI 
1640. Cells (106 PBMCs/ml/well) were activated by incubation with phy-
tohemagglutinin-P 1/700 (PHA, Bacto PHA-P; Becton Dickinson), alone 
or in combination with recombinant IFN-γ (5,000 IU/ml; Imukin, Boeh-
ringer Ingelheim) or recombinant IL-12p70 (20 ng/ml; R&D System) or 
IL-23 (20 ng/ml; R&D Systems), anti-CD3 antibody (10 ng/ml, OKT3, 
OrthoPharmaceutical) and LPS (from Salmonella minnesota, 1 μg/ml; Sigma-
Aldrich) for 14 and 48 h.
Culture and stimulation of cell lines. Fibroblast cell lines were derived 
from dermal biopsy samples from patients and healthy donors and immor-
talized by transformation with a plasmid-containing SV40 large T antigen. 
We added 105 fi broblasts to DMEM (GIBCO BRL) supplemented with 
10% (vol/vol) heat-inactivated FBS (GIBCO BRL) in each well of a 
24-well plate. Fibroblasts were stimulated with TNF-α (20 ng/ml; R&D 
Systems), IL-1β (10 ng/ml; R&D Systems), or PMA (10−7 M; Sigma-
 Aldrich) plus ionomycin (10−5 M; Sigma-Aldrich) and supernatants were 
recovered after 24 h of activation. B lymphocytes were immortalized with 
Epstein-Barr virus (EBV-transformed B cells) and cultured in complete 
RPMI 1640. EBV-transformed B cells were stimulated with imidazoquino-
lone R-848, an agonist of TLR-7 and TLR-8 (provided by R. Miller, 3M 
Pharmaceuticals and 3M Innovative Properties Company, St. Paul, MN) 
for 24 h.
Genetic analysis. Genomic DNA was isolated by phenol/chloro-
form extraction from blood cells, which were washed in TE 10:1 buff er 
(10 mM Tris, 1 mM EDTA, pH 7.6) and lysed in extraction buff er 
(10 mM Tris, 0.1 M EDTA, 0.5% SDS, and 10 mg/ml proteinase K) over-
night at 37°C. RNA was extracted from EBV-transformed B cell lines or 
SV40-transformed fi broblasts with TRIzol (Invitrogen), according to the 
kit manufacturer’s instructions. We used 1–5 μg total RNA for direct 
reverse transcription with Oligo-dT (Invitrogen). PCR was performed 
using Taq polymerase (Invitrogen), and the GeneAmp PCR System 9700 
(Applied Biosystems). Primer sequences for the amplifi cation of NEMO 
exons and cDNA are available upon request. PCR products were purifi ed 
by centrifugation through Sephadex G-50 Superfi ne resin (GE Healthcare) 
and sequenced with the BigDye Terminator Cycle sequencing kit (Applied 
 Biosystems). Sequencing products were purifi ed on Sephadex G-50 Superfi ne 
resin and sequences were analyzed on a 3100 ABI Prism Genetic Analizer 
(Applied Biosystems).
Western blot and EMSA. For EMSAs, nuclear extracts were prepared 
from SV40-transformed fi broblasts, after incubation with or without IL-1β 
(10 ng/ml) and TNF-α (20 ng/ml) for 20, 40, and 60 min. We used the 
Bio-Rad Laboratories protein assay to adjust protein concentrations such 
that all samples contained similar amounts of protein. EMSA was performed 
with a [32P]-labeled NF-κB–specifi c DNA probe (5′-G A T C A T G G G G A A-
T C C C C A -3′, 5′-G A T C T G G G G A A T T C C C C C A T -3′). For Western 
blotting, total protein was extracted from SV40-transformed fi broblasts and 
EBV-transformed B cells. Cytosolic extracts were prepared from SV-40–
transformed fi broblasts with or without stimulation with IL-1β (10 ng/ml) 
and TNF-α (20 ng/ml). Protein fractions were separated by reducing SDS-
PAGE and electrotransfered onto nitrocellulose membranes (Schleicher & 
Schuell). Membranes were blocked by incubation in 5% nonfat milk powder 
(Nestle USA) in 0.05% Tween-20 in PBS for 60 min at room temperature. 
NEMO was detected using rabbit polyclonal anti-NEMO antibodies (3328 
and p18, gifts from G. Courtois, INSERM, Saint Louis Hospital, Paris, 
France), rabbit antibodies against GAPDH (SC-25778, Santa Cruz Biotech-
nology, Inc.), rabbit anti-IκBα (C-21, sc-37, Santa Cruz Biotechnology, Inc.), 
and mouse antibodies against Stat-3 (Santa Cruz Biotechnology, Inc.). 
Membranes were washed several times in 0.05% Tween-20 in PBS, and an-
tibody binding was detected by incubation with horseradish peroxidase–
conjugated anti–rabbit secondary antibodies (GE Healthcare), using the ECL 
system (GE Healthcare).
Purifi cation of peripheral T cells and monocytes. For T cell isolation, 
we depleted peripheral PBMCs of adherent cells and performed negative 
immunomagnetic depletion using a cocktail of antibodies against CD14, 
CD16, CD19, CD36, CD56, CD123, and glycophorin A (Macs; Miltenyi 
Biotec), according to the kit manufacturer’s instructions. The preparation 
was >95% pure, as assessed by fl ow cytometry with FITC-CD2 and PE-
CD3 staining (BD Biosciences). Monocytes were isolated from peripheral 
PBMCs by negative immunomagnetic depletion, using a cocktail of anti-
bodies against CD3, CD7, CD16, CD19, CD56, CD123, and glycophorin 
A (Macs; Miltenyi Biotec), according to the kit manufacturer’s instructions. 
Monocytes were >80% pure, as assessed by fl ow cytometry with PE-CD14 
(BD Biosciences) staining.
Coculture of monocytes and T cells. We plated 105 monocytes per 
well in complete RPMI 1640 medium in 24-well plates (Nunc) and incu-
bated them for 3 h at 37°C in an atmosphere containing 5% CO2. The 
nonadherent cells were washed off  and the adherent cells were incubated 
overnight with 400 μl of complete RPMI 1640. The following day, T cells 
were purifi ed as described in a previous paragraph and 5 × 105 T cells were 
added to the monocytes. Selected wells were stimulated with a 1/700 dilu-
tion of PHA (Bacto PHA-P; Becton Dickinson), alone or in combination 
with recombinant IFN-γ (5,000 IU/ml; Imukin, Boehringer Ingelheim, 
France), recombinant IL-12p70 (20 ng/ml; R&D Systems), and recombi-
nant IL-23 (20 ng/ml; R&D Systems). Supernatants were collected 14 and 
48 h after activation.
Generation of dendritic cells from purifi ed monocytes. MDDCs 
were obtained from purifi ed monocytes as described in a previous 
 paragraph. They were incubated for 2 h in complete RPMI 1640 medium 
at 37°C under an atmosphere containing 5% CO2 to remove all nonadh-
erent cells, thereby increasing purity. The adherent cells were cultured in 
complete RPMI 1640 in the presence of GM-CSF (50 ng/ml; R&D 
 Systems) and IL-4 (10 ng/ml; R&D Systems). Optimal conditions were 
maintained by splitting these cultures every 2 d. Cells were collected on 
day 7, when the cultures contained >95% immature CD1a+ (BD Biosciences) 
dendritic cells.
CD40 activation. Mouse fi broblastic L-cells transfected with the human 
 ligand of CD40 (L-cell-hCD40L) were used to induce CD40 activation on 
MDDCs. Nontransfected L-cells were used for control cultures. L-cells were 
fi rst treated with 10 μg/ml mitomycin (Sigma-Aldrich) in sterile 1 x PBS for 
2 h at 37°C in 5% CO2. L-cells were washed fi ve to seven times in 1 x PBS 
to remove all trace of mitomycin. We then plated 104 L-cells per well in 24-
well plates and incubated them for 2 d in complete RPMI 1640 at 37°C in 
an atmosphere containing 5% CO2. We incubated 2 × 105 MDDCs in 
complete RPMI 1640 with mitomycin-treated L-cells and recovered cell-
free supernatants for cytokine analysis and MDDCs for cell surface pheno-
typing of CD40, CD80, and CD86 (BD Biosciences) by fl ow cytometry 24 h 
later. CD40 was activated on B cells with a mixture of soluble recombinant 
CD40L (500 ng/ml; Amgen) and IL-4 (100 IU/ml; R&D Systems). In brief, 
PBMCs were cultured for 5 d for proliferation (assessed by [3H]thymidine 
incorporation) assays and 12 d for the measurement of IgE production 
 (assessed by ELISA) as previously described (43).
Flow cytometry. For the staining of NEMO in EBV-transformed 
B cells, fi broblastic cell lines, and highly purifi ed monocytes and T cells 
isolated from PBMCs, we fi xed 2 × 105 cells with 4% paraformalde-
hyde (PFA, Fluka) in 1 x PBS and permeabilized the cells by incubation 
in 0.1% saponin (Sigma-Aldrich) in PBS. The cells were incubated with 
anti-NEMO (611306; BD Biosciences) antibody and the corresponding 
mouse IgG1  isotype (BD Biosciences), and primary antibody binding was 
detected by  incubation with Alexa Fluor 488–labeled anti–mouse antibodies 
 (Invitrogen). Cell surface phenotyping was performed by fl ow cytometry, 
in MDDCs  incubated with L-cell or L-cell-hCD40L, using directly labeled 
 antibodies. Dual-color fl uorescence assays were performed with PE-CD1a 
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(BD  Biosciences) in combination with FITC-CD40, FITC-CD80, and 
FITC-CD86 (all from BD Biosciences). The respective isotype controls 
were performed with mouse PE-IgG2k (BD Biosciences) and mouse FITC-
IgG1k (BD Biosciences). Fluorescence was analyzed with a FACScan appara-
tus (Becton Dickinson), using CELLQuest software.
Cytokine analysis. Cytokine concentrations in supernatants were mea-
sured by two-sided sandwich ELISA, according to the kit manufacturer’s in-
structions: IL-12p40, IL-12p70, G-CSF (R&D Systems), and TNF-α, 
IFN-γ, IL-10, IL-6, IL-8 (Sanquin). Multiplex cytokine assays were also 
performed on culture supernatants, using a cocktail of 17 cytokines: IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17, TNF-α, 
IFN-γ, GM-CSF, G-CSF, MCP-1, and MIP-1β (Bio-Plex Suspension 
 Array System).
Structural modeling of the NEMO oligomerization domain. The 
NEMO sequence encompassing the CC2-LZ region is not >30% of iden-
tity to any reference protein in the Protein Data Bank. We therefore used 
experimental data to search for compatible structure references. The NEMO 
oligomerization domain forms a globular trimer by equilibrium sedimenta-
tion with a hydrodynamic radius of 26.1 Å, as shown by gel fi ltration (30) 
and dynamic light scattering (unpublished data), and the CC2 and LZ coiled-
coil subdomains interact by fl uorescence polarization (30). Limited proteoly-
sis in combination with mass spectrometry identifi ed a trypsin-sensitive site 
at residue Lys302, coinciding with the loop connecting the CC2 and LZ 
coiled-coils (unpublished data). Finally, the CD spectrum of the trimer 
showed it to contain 92% α-helix at 277 K (unpublished data). Based on 
these data, we used the HIV-1 gp41 ectodomain (PDB no. 1F23; reference 31) 
as a structure reference to provide atomic coordinates. The trimeric 
CC2-LZ domain of NEMO was modeled using the Insight II program 
 (Accelrys, Inc.). The model was constructed by manually docking the Cα 
backbone of the CC2 coiled-coil (residues 260–292) with that of the LZ 
coiled-coil (residues 306–344) in an antiparallel manner. During docking, 
we looked for unfavorable and favorable contacts between the CC2 and LZ 
atoms, by calculating electrostatic and van der Waals interaction energies, 
using the Docking module of Insight II. The resulting energy-minimized 
model is shown in Fig. 2.
Immunofl urescence microscopy. MDDCs were allowed to diff erentiate 
and were activated by CD40L-expressing fi broblasts, as previously described. 
MDDCs were immediately fi xed upon activation, by incubation in 4% 
formaldehyde/PBS at 4°C for 20 min, followed by surface staining with 
mouse anti–huamn CD1a (BD Biosciences) at 4°C for 15 min. Cells were 
washed in PBS and incubated with goat Cy3-conjugated anti–mouse IgG 
antibody (Zymed Laboratories). For intracellular staining, MDDCs were 
permeabilized by incubation in 0.2% Triton X-100 (Sigma-Aldrich) in PBS 
for 15 min. Cells were washed twice in PBS, blocked by incubation with 
FcR-blocking reagent (Macs; Miltenyi Biotec) for 20 min and washed once 
with PBS. MDDCs were incubated with 1 μg primary  antibody/PBS, rabbit 
anti-p65 (C20, Santa Cruz Biotechnology, Inc.) and rabbit anti–c-Rel (C; 
Santa Cruz Biotechnology, Inc.) at 4°C for 30 min and were washed with 
PBS. Cells were incubated with Alexa 488– conjugated goat anti–rabbit IgG 
antibody (1:300 dilution) (Invitrogen) and with 4,6-diamidino-2-phenylin-
dole (DAPI) (1/10,000 dilution;  Invitrogen) for 15 min. They were washed 
at least three times with PBS. MDDCs were resuspended in 100 μl of PBS 
and plated on lysine-coated slides (VWR), using the Cytospin system. The 
coverslips were mounted on glass slides with Mowiol. Slides were viewed 
under an LSM 510  confocal microscope.
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